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ABSTRACT
Objective: A randomised double-blind placebo controlled
withdrawal clinical trial of prednisone versus placebo in
patients with rheumatoid arthritis (RA), treated in usual
clinical care with 1–4 mg/day prednisone, withdrawn to
the same dose of 1 mg prednisone or identical placebo
tablets.
Methods: All patients were from one academic setting
and all trial visits were conducted in usual clinical care.
Patients were taking stable doses of 1–4 mg prednisone
with stable clinical status, documented quantitatively by
patient questionnaire scores. The protocol included three
phases: (1) equivalence: 1–4 study prednisone 1 mg
tablets taken for 12 weeks to ascertain their efficacy
compared with the patient’s usual tablets before
randomisation; (2) transfer: substitution of a 1 mg
prednisone or identical placebo tablet every 4 weeks
(over 0–12 weeks) to the same number as baseline
prednisone; (3) comparison: observation over 24 sub-
sequent weeks taking the same number of either placebo
or prednisone tablets as at baseline. The primary outcome
was withdrawal due to patient-reported lack of efficacy
versus continuation in the trial for 24 weeks.
Results: Thirty-one patients were randomised, 15 to
prednisone and 16 to placebo, with three administrative
discontinuations. In ‘‘intent-to-treat’’ analyses, 3/15
prednisone and 11/16 placebo participants withdrew
(p=0.03). Among participants eligible for the primary
outcome, 3/13 prednisone and 11/15 placebo participants
withdrew for lack of efficacy (p=0.02). No meaningful
adverse events were reported, as anticipated.
Conclusion: Efficacy of 1–4 mg prednisone was
documented. Evidence of statistically significant differ-
ences with only 31 patients may suggest a robust
treatment effect.
The use of glucocorticoids in the treatment of
rheumatoid arthritis (RA) has evoked controversy
for more than half a century.
1–5 Disease modifica-
tion was documented during the 1950s,
6 but
toxicities of long-term glucocorticoids in pharma-
cological doses of prednisone or prednisolone of
10 mg/day or more, as was the clinical practice in
the 1950s,
7 were inevitable. Therefore, from the
1950s through the 1980s, systemic glucocorticoids
were recommended in RA only as ‘‘bridging
therapy’’ while awaiting anticipated benefits of
disease-modifying antirheumatic drugs
(DMARDs), or for acute severe disease flares or
life-threatening vasculitis.
A reassessment began during the 1980s, based on
recognition of severe long-term outcomes of RA
89
and clinical experience indicating relatively limited
toxicity associated with low doses of glucocorti-
coids. An open study,
10 a 24-week non-blinded
clinical trial
11 and recent double-blind clinical
trials
12–17 have recognised clinical benefit, including
‘‘disease-modifying’’ properties, of low-dose pred-
nisone in slowing radiographic progression, con-
firmed in meta-analyses.
18 19 Reports indicating
disease modification even with low doses of
prednisone or prednisolone of 5–7.5 mg/day
12 16 17
are of particular interest, as doses of 10 mg/day are
associated with adverse outcomes
20 including bone
loss
21 and higher mortality rates.
22 23
Prednisone or prednisolone for RA generally is
initiated with a dose of 10–20 mg/day and main-
tained at levels of 5 mg/day or more. The medical
literature includes varying criteria for ‘‘low-dose’’
prednisone, generally 5 mg or 10 mg/day. A few
clinicians, including the senior author, have treated
most patients over the last decade with an initial
dose of 3 mg/day.
The efficacy of prednisone in doses of ,5 mg/
day has not been established in patients with RA,
and rheumatologists continue to disagree on the
use of glucocorticoids. A double-blind clinical trial
to analyse the efficacy of ,5 mg/day prednisone
would therefore appear desirable. A large multi-
centre prospective randomised double-blind clinical
trial in patients with no previous glucocorticoid
therapy, to be taken with their usual RA treat-
ment, might appear ideal. However, resources for
such a multicentre clinical trial have not been
available. Therefore, with partial support from the
United States Arthritis Foundation, we performed
a single-centre withdrawal trial of prednisone
,5 mg/day in the course of usual care.
METHODS
Patients
All patients were recruited from one academic
clinical care setting at Vanderbilt University and all
clinical trial visits were conducted during usual
clinical care. Most patients with RA in this clinical
setting have been treated with long-term predni-
sone 1–5 mg/day, with a usual initial dose of 3 mg/
day since the mid-1990s. Clinical efficacy without
severe toxicity has been observed,
24 although
almost all patients are also treated with metho-
trexate so the specific efficacy of prednisone could
not be analysed without a clinical trial.
Withdrawal clinical trial protocol
Patients with stable clinical status who were
taking stable doses of prednisone 1–4 mg/day in
1 mg tablets or one 5 mg tablet per day (although
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the previous 12 weeks were invited to participate in a
randomised double-blind placebo controlled prednisone with-
drawal clinical trial. All participants gave informed consent to
participate. The trial was approved by the Institutional Review
Board of Vanderbilt University, and supported in part by the
United States Arthritis Foundation.
The trial was designed to be broadly inclusive with few
exclusion criteria. Inclusion criteria were: age at least 18 years;
met American Rheumatism Association (ARA) criteria for RA;
25
had been taking a stable dose of 1–5 mg/day prednisone for at
least 12 weeks with no anticipated dose change. Stable clinical
status was documented by an absolute change of less than 3
units from 12 weeks earlier in routine assessment of patient
index data 3 (RAPID3), an index of the three patient-reported
outcomes, on a multidimensional health assessment question-
naire (MDHAQ)
26 for physical function, pain and global
estimate of status, each scored 0–10, total 0–30,
27 completed
by all patients at all visits as a component of the infrastructure
of standard care.
28
Exclusion criteria were relatively few: no prednisone therapy;
prednisone dose .5 mg/day; improving or worsening clinical
status; anticipation of joint replacement or other elective
surgery; uncontrolled hypertension, diabetes or other comorbid-
ities; severe fibromyalgia; inability to complete English language
questionnaires; and pregnancy or nursing.
The protocol included three phases:
c Equivalence: all participants were given a 12-week (84-day;
actually 100 days to ensure availability) supply of ‘‘study
prednisone’’ tablets to take at the same dose as at baseline
before entry into the clinical trial. These tablets were taken
in lieu of the patients’ usual prednisone obtained at their
own pharmacies to ascertain similar efficacy of the study
prednisone to the usual prednisone.
c Transfer: participants who reported ‘‘equivalence’’ over the
12-week period were assigned randomly to be ‘‘transferred’’
at a rate of a single 1 mg tablet per 4 weeks over the next 0–
12 weeks from study prednisone tablets to either 1 mg
prednisone or identical placebo tablets (table 1). The gradual
transfer was performed to avoid abrupt reduction of
prednisone usage in subjects randomised for transfer to
placebo.
c Comparison: participants were maintained over 24 weeks
following the ‘‘transfer’’ phase on the same number of either
1 mg prednisone or identical placebo tablets as at baseline.
Each visit included assessment and recording of weight and
blood pressure; completion of an MDHAQ by the patient and
scoring of RAPID3 by the rheumatologist; and laboratory tests
of erythrocyte sedimentation rate (ESR), C-reactive protein
(CRP), liver function and haematological status to monitor
possible adverse events of prednisone or concomitant metho-
trexate or other medications.
29
Prednisone and placebo tablets
Prednisone 1 mg tablets and identical placebo tablets were
purchased from Apotex Inc, Toronto, Canada. Tablets were
packaged in bottles containing 100 tablets each. The bottles
were relabelled at the trial site with two types of labels: ‘‘Bottle
A’’, known to be prednisone, and ‘‘Bottle B’’ which contained
‘‘unknown’’ tablets (either prednisone or placebo). The appro-
priate number of Bottle A study prednisone tablets in bottles of
100 tablets (according to the daily dose at baseline (1–5 mg/day;
no patient enrolled took 5 mg/day)) was given to each
participant for a 100-day supply during the 12-week (84-day)
‘‘equivalence’’ phase.
Packets were prepared for visits 2, 3 and 4 based on the
participant’s daily baseline dose (1–5 mg/day), according to a
randomisation scheme in groups of 4 (2 prednisone and 2
placebo) for each dose. Packets for the entire study were
prepared for 68 possible participants, 8 each for prednisone dose
levels of 1, 2, 4 or 5 mg/day and 36 for 3 mg/day, taken by the
majority of patients before the trial. Study packets included the
appropriate number of ‘‘Bottle A’’ bottles of 100 1 mg
prednisone tablets and ‘‘Bottle B’’ bottles of 1 mg prednisone
or identical placebo tablets (table 1).
Study visits
Visit 1 included an explanation of the trial and completion of
informed consent. Participants were given a 12-week supply
(with tablets for 16 extra days) of ‘‘Bottle A’’ 1 mg study
prednisone tablets to take instead of their usual daily
prednisone dosage for 12 weeks. This phase was designed to
establish whether or not ‘‘equivalence’’ of the same dose of
study prednisone to the patient’s usual prednisone tablets could
be seen.
Visit 2 occurred 12 weeks later. Participants who reported
‘‘equivalence’’ of study prednisone to their usual prednisone
dose over the 12 weeks and elected to continue in the study
were randomised to either 1 mg prednisone or identical placebo
tablets for the ‘‘transfer’’ phase. Each participant received a
specific written schedule with specific dates every 4 weeks to
reduce by one the number of tablets to be taken from ‘‘Bottle
A’’ (of 1 mg prednisone tablets) and to increase by one the
Table 1 Plan to ‘‘transfer’’ patients from low-dose prednisone tablets to study prednisone or placebo tablets
Dose Medication
Week of ‘‘transfer’’ phase
Week 0 Week 4 Week 8 Week 12 Week 16*
1 mg Bottle A (prednisone) 0
Bottle B (unknown) 1
2 mg Bottle A (prednisone) 1 0
Bottle B (unknown) 1 2
3 mg Bottle A (prednisone) 2 1 0
Bottle B (unknown) 1 2 3
4 mg Bottle A (prednisone) 3210
Bottle B (unknown) 1234
5 mg Bottle A (prednisone) 4321 0
Bottle B (unknown) 1234 5
Each participant was given an individual schedule outlining specific dates to make changes in the number of tablets to be taken
from bottle A and bottle B.
*No patients taking 5 mg at baseline were enrolled in the study.
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prednisone or identical placebo tablets) over a 12-week period.
Substitution of one ‘‘Bottle B’’ tablet for one ‘‘Bottle A’’ tablet
occurred at 0, 4, 8, 12 and 16 weeks for 1, 2, 3, 4 and 5 mg
baseline dose, respectively (no enrolled participant was taking
5 mg/day). Therefore, at the end of the 12-week period, each
participant was taking only ‘‘Bottle B’’ study medication. The
gradual tapering was designed to avoid an abrupt discontinua-
tion of prednisone which might favour prednisone.
Visit 3 occurred 4–12 weeks after visit 2 (or was omitted for
participants with a baseline dose of 1 mg/day). All participants
whose baseline daily dose was 2–4 mg prednisone then started
taking only unknown Bottle B prednisone or placebo and began
the ‘‘comparison’’ phase.
Visit 4 occurred 12 weeks after visit 3. Participants completed
the usual MDHAQ and the trial status was reviewed with the
investigator.
Visit 5 occurred 12 weeks after visit 4, at least 24 weeks after
participants had completed the ‘‘transfer’’ phase. The partici-
pants completed the final usual MDHAQ and prednisone was
reinstated at the pretrial dose.
Clinical trial outcomes
The predetermined primary outcome was withdrawal (‘‘drop-
out’’) after visit 2 due to perceived lack of efficacy of study
tablets (prednisone or placebo), ie, during the ‘‘transfer’’ or
‘‘comparison’’ phases of the trial, versus remaining in the trial
until completion of the 24-week ‘‘comparison’’ period.
Secondary outcomes included a change in any of the three RA
Core Data Set variables
30 found on the MDHAQ (as well as the
HAQ) for physical function, pain and global estimate, all scored
0–10, and RAPID3 0–30 composite scores. Weight, systolic and
diastolic blood pressure and laboratory tests of ESR, CRP,
haematology and liver profiles were recorded at each visit and
analysed as indicators of possible adverse events.
Data management and statistical analyses
All ‘‘case report forms’’ were the routinely administered
MDHAQ and a physician-completed data sheet that included
blood pressure, weight and all medications. These data were
entered into a Microsoft Access database maintained on all
patients seen at each visit in this setting and transferred to Stata
V.9.2 (College Station, Texas, USA). The prednisone dose at
baseline of all participants was compared descriptively with the
initial dose of prednisone taken by patients at their first visit to
this setting 1–15 years earlier.
Differences between treatment groups were evaluated using
the Wilcoxon rank sum test for continuous variables or the
Fisher exact test for categorical variables. The primary analysis
and an intention-to-treat analysis of all randomised participants
were conducted using the Fisher exact test to assess statistical
significance. Differences between treatment groups with respect
to changes from visit 1 to visit 5 or final visit for physical
function score (0–10), pain visual analogue scale (VAS) score (0–
10), patient global VAS score (0–10), RAPID3 composite score
(0–30), fatigue VAS score (0–10), morning stiffness (minutes),
weight, systolic/diastolic blood pressure, ESR and CRP levels
and other laboratory tests were evaluated using the Wilcoxon
rank sum test.
RESULTS
Patient recruitment
Enrolment was conducted over 17 months from March 2005 to
July 2006. Overall, 156 patients with RA were seen over this
period. Although the trial was designed with liberal inclusion
criteria and minimal exclusion criteria, only 37 of these 156
patients met the enrolment criteria and volunteered to
participate. The reasons for non-participation included: 21
(13.5%) unwilling to discontinue taking prednisone, often
noting previous efforts without success, at the advice of
physicians, relatives and others; 21 (13.5%) clinically improving
(RAPID3 lower by >3 units) or with new RA therapies; 9
(5.8%) clinically declining (RAPID3 higher by >3 units) with
need for new therapies; 14 (9%) with severe fibromyalgia; 15
(9.6%) too far away for 3-monthly visits; 1 (0.6%) could not
complete an English language questionnaire; 19 (12.2%) took a
prednisone dose of .5 mg/day (all initiated by other physi-
cians); 5 (3.2%) were not taking any prednisone; 4 (2.6%) with
severe clinical status for whom the investigator regarded it as
inappropriate clinically to discontinue prednisone; 3 (1.9%)
pregnant or nursing; 5 (3.2%) with substantial comorbidities;
and 2 (1.3%) with planned elective surgery. Thus, only 37 of the
156 patients with RA (23.7%) were eligible and volunteered to
participate (table 2).
Of the 37 patients who agreed to participate in the trial, 6
(16.2%) reported that study prednisone was ineffective during
the 12-week ‘‘equivalence’’ period compared with their usual
prednisone (although the study tablets met US Food and Drug
Administration (FDA) requirements) and declined to continue.
Thus, 31 participants were randomised, 15 to the prednisone
group and 16 to the placebo group.
Participant enrolment in clinical trial
The participants randomised to prednisone and placebo did not
differ significantly in age or any quantitative or laboratory
measure (table 3). The mean prednisone dose at baseline was
2.9 mg/day and the median dose was 3 mg/day in both groups.
Other treatments taken included methotrexate at doses
between 5 and 25 mg/week by all but 2 participants; hydroxy-
chloroquine by 10 participants (8 in combination with
methotrexate), 5 in the prednisone group and 5 in the placebo
group; leflunomide by 2 participants in the prednisone group;
etanercept by 3 participants, 2 in the prednisone group and 1 in
the placebo group; and adalimumab by 1 participant in the
placebo group.
Among the 31 participants, 22 had a baseline prednisone dose
of 3 mg/day, 5 of 4 mg/day, 3 of 2 mg/day and 1 of 1 mg/day
Table 2 Low-dose prednisone versus placebo in rheumatoid arthritis:
enrolment results in 156 patients with rheumatoid arthritis
Total number of rheumatoid arthritis patients seen 156 (100%)
Improving or recently begun on new arthritis therapy 21 (13.5%)
Declining status 9 (5.8%)
Fibromyalgia as a major clinical problem 14 (9.0%)
Administrative: lives too far away 15 (9.6%)
Language barrier to completion of questionnaire 1 (0.6%)
Prednisone dose .5 mg/day 19 (12.2%)
Not taking any prednisone 5 (3.2%)
Refused to discontinue prednisone 21 (13.5%)
Comorbidity (AIDS, cancer, etc) 5 (3.2%)
Severe status (investigator not willing to risk discontinuing prednisone) 4 (2.6%)
Pregnant or nursing 3 (1.9%)
Surgery planned 2 (1.3%)
Enrolled 37 (23.7%)
Changed mind before randomisation 6 (3.8%)
Total randomised 31 (19.9%)
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1–15 years earlier had been 3 mg in 20 patients, 5 mg in 8
patients and 4 mg, 6 mg and 7.5 mg in each of 3 additional
patients (table 4). The 15 participants randomised to receive
prednisone included 1 with a baseline dose of 1 mg/day, 2 of
2 mg/day, 10 of 3 mg/day and 2 of 4 mg/day (table 5). Among
the 16 participants randomised to receive placebo, 1 had a
baseline dose of 2 mg/day, 12 of 3 mg/day and 3 of 4 mg/day
(table 5).
Withdrawal clinical trial results
Of the 15 participants randomised to the prednisone group, 2
were withdrawn for administrative reasons, one for an
unexpected hysterectomy and the other for a recurrence of
breast cancer. Of the 13 remaining participants in the
prednisone group, 3 withdrew for lack of efficacy and 10
completed the 24-week ‘‘comparison’’ observation period
(table 5).
Of the 16 participants randomised to the placebo group, 1
was withdrawn for administrative reasons; the patient had
severe weight loss which was ultimately found to be based on
depression, with discontinuation all medications. Of the 15
remaining participants in the placebo group, 11 withdrew for
lack of efficacy and 4 completed the 24-week ‘‘comparison’’
observation period (table 5).
Differences between withdrawals in the prednisone group
and the placebo group were statistically significant (p=0.021,
table 5). An intent-to-treat analysis of all randomised partici-
pants also indicated significant differences (p=0.032, table 5).
Participants in the placebo group had higher median changes
(indicating poorer status) with worsening scores for physical
function, pain, patient global estimate, RAPID3 and fatigue.
Participants in the prednisone group remained similar to
baseline at the conclusion of the trial (table 6), although none
of the differences were statistically significant compared with
the placebo group (p.0.05). Furthermore, no significant
differences were seen between the groups for changes in ESR
or CRP levels.
Adverse events
No meaningful toxicities were reported by the participants in
either group, as anticipated, since all participants had been
taking stable doses of 1–4 mg/day prednisone before the trial,
many for long periods. No significant changes in weight or
blood pressure were seen within either group or between
groups.
DISCUSSION
The results of this withdrawal clinical trial indicate that
patients who were transferred from long-term prednisone doses
of 1–4 mg/day to identical placebo tablets were significantly
more likely to withdraw over a subsequent 6–9-month period
than those who were randomised to prednisone. These results
may appear surprising as most rheumatologists initiate (and
often maintain) prednisone treatment at doses higher than
3 mg. By contrast, most participants in the clinical trial reported
here had never taken prednisone at a dose higher than 3 mg, and
the efficacy of this dose compared with placebo was documen-
ted in the trial.
This trial has many limitations. First, the number of
participants is small, although a finding of statistically
significant differences with only 31 participants may imply a
robust treatment effect. Second, all participants were from one
academic clinical practice and may not be representative of all
patients with RA. A multicentre trial to improve generalisability
of the results would be desirable. Third, a trial of initiation of
prednisone 3 mg/day in patients who had never been treated
previously with prednisone, rather than withdrawal from
prednisone, might give more definitive information. However,
a period of years would be required to accumulate a sufficient
number of patients from one rheumatologist, and resources for
performance of a multicentre trial have not been available.
Fourth, the trial was conducted entirely in the course of usual
clinic visits, without a study coordinator who might have added
rigor to the results. However, the costs of this trial were
substantially lower than in usual clinical trials and the primary
outcome of withdrawal for lack of efficacy was accounted for in
all 31 enrolled patients. It might be possible to conduct large
simple clinical trials
31 32 in RA using only patient self-report
measures and indices that include only these data. Self-report
measures and indices distinguish active from control treatment
as significantly as joint counts, laboratory tests or indices
requiring these data in reported clinical trials of RA.
33 34
It was disappointing that only 37 of 156 consecutive patients
with RA seen over 17 months were eligible and volunteered to
Table 3 Baseline mean level or percentage of participants randomised
to placebo or prednisone
Variable
Placebo
(N=16)
Prednisone
(N=15)
Demographic variables
Age (years) 50.1 53.3
Female (%) 62.5% 66.7%
Education (years) 13.5 15.1
Disease variables
Disease duration (years) 4.4 8.1
Erythrocyte sedimentation rate
(,28 mm/h)
18.9 14.6
C-reactive protein (0–10) 8.0 6.3
Questionnaire variables
Physical function score (0–10) 1.02 1.36
Pain VAS score (0–10) 1.64 1.68
Global VAS score (0–10) 1.41 1.83
RAPID3 score (0–30) 4.07 4.87
Fatigue VAS score (0–10) 1.85 2.16
Morning stiffness (minutes) 38.8 21.7
Medication variables
Methotrexate 93.8% 93.3%
Hydroxychloroquine 31.3% 33.3%
Leflunomide 0% 13.3%
Etanercept 6.3% 13.3%
Adalimumab 6.3% 0%
No differences between groups were statistically significant (p,0.05)
RAPID3, routine assessment of patient index data 3; VAS, visual analogue scale.
Table 4 Initial prednisone dose at clinical setting 1–15 years before
the clinical trial compared with prednisone dose at enrolment in clinical
trial
Initial prednisone
dose
Clinical trial dose
Total 1 mg 2 mg 3 mg 4 mg
3m g 1 3 1 5 1 2 0
4m g – – 1 – 1
5m g – – 4 4 8
6m g – – 1 – 1
7.5 mg – – 1 – 1
Total 1 3 22 5 31
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observation that only a small fraction of patients with RA seen
in this setting in the year 2000 were eligible for trials of anti-
tumour necrosis factor a.
35 Documentation of stable clinical
status according to MDHAQ-RAPID3 data rather than non-
quantitative clinical judgement may have introduced greater
stringency in enrolment. In most clinical trials involving
patients with ‘‘incomplete responses’’ to methotrexate, ‘‘stable’’
clinical status is based on clinical judgement rather than on
quantitative data. This may explain why ACR20 responses in
the range of 20–30% are seen in patients randomised to control
treatment
36 in ‘‘add-on’’ clinical trials of biological agents.
37 A
requirement for stable questionnaire scores over a 3-month
period to document incomplete (or complete, stable or unstable)
responses could reduce background responses in control arms of
clinical trials of RA.
The reported trial may underestimate the treatment effects of
prednisone, given that a primary reason for non-participation
was a desire not to discontinue prednisone on the basis of failure
of (often many) previous attempts. It is not clear why the six
participants who withdrew before randomisation may have
experienced lower efficacy with study prednisone than with
their own prednisone. Although generic medications are
required to meet chemical criteria for equivalence, anecdotal
information suggests that some patients may vary in response
to different brands of generic medications.
Neither efficacy nor safety of long-term low-dose prednisone
can be established definitively from the results of this clinical
trial. Long-term safety remains of concern. Higher mortality
rates have been associated with the use of prednisone in an
earlier cohort of patients seen by the senior author at Vanderbilt
University
22 and by others.
23 38 However, results of observational
studies reporting adverse outcomes of glucocorticoids are
confounded by indication, as patients with more severe clinical
status are more likely to be treated with glucocorticoids.
Furthermore, almost all patients in the previously reported
studies had been treated with prednisone doses greater than
10 mg/day, many for extended periods.
Most participants in the present study never took doses of
prednisone greater than 3 mg/day, with mean RAPID3 scores at
baselineof ,6onascaleof 0–30,indicating lowseverity.
27Limited
data are available concerning long-term mortality outcomes in
such patients, although MHAQ physical function scores of ,1.2
on a scale of 0–10 (0.6 on a scale of 0–3) are associated with
favourable long-term mortality outcomes compared with all
patients with RA.
39 In one study of cardiovascular disease
associated with long-term glucocorticoid use, patients whose
dose was 5 mg showed no differences from control subjects.
40
Large prospective studies as well as long-term observations of
patients such as those in the present study, treated with
prednisone only in doses of 5 mg/day or less, are needed to clarify
possible effects of very low-dose prednisone on mortality.
We conclude that this clinical trial documents the efficacy of
low-dose prednisone in patients with RA. Although not
analysed in this study because of the short time frame, we
have observed minimal long-term adverse events in patients
who have taken daily prednisone for more than 10 years,
sometimes up to 20 years. A multicentre long-term (2 years)
‘‘de novo’’ clinical trial of prednisone in new patients who have
not had any prior glucocorticoid treatment would be of
considerable value.
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